Trial Profile
PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Valsartan (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms PRAETORIAN-COVID
- 19 Sep 2021 Status changed from recruiting to discontinued. (Enrollment was stopped to facilitate successful enrollment for the ACE2RAS-domain of theREMAP-CAP trial.)
- 23 Jun 2021 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.
- 25 May 2020 Planned End Date changed from 1 Oct 2021 to 1 Dec 2021.